Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flunarizine + propranolol
- Development stage
- Unknown
- Lead developer
- Brainwave
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flunarizine + propranolol is a fixed-dose combination of a calcium channel blocker and a beta-blocker, primarily indicated for the prophylaxis of migraine. Flunarizine acts by inhibiting T-type and L-type calcium channels, reducing calcium influx into neurons and vascular smooth muscle, and also exhibits antihistaminic properties. Propranolol is a non-selective beta-adrenergic receptor antagonist that reduces migraine frequency by stabilizing cranial blood vessels and modulating central serotonergic and adrenergic pathways. This combination is marketed by Brainwave Healthcare as a branded generic in India for patients requiring dual-action preventive therapy to reduce the frequency and severity of migraine attacks.
- Brand names
- FLUNAWAVE-P
- Other names
- flunarizine and propranololpropranolol and flunarizineFlunarizine + Propranolol combination
02
Targets
NaV (Voltage-gated sodium channels)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)ADRB2 (β2)ADRB1 (β1)ADRB3 (β3)KCNH2 (Voltage-gated potassium channel subfamily H member 2)CACNA1A (P-type Calcium Channel)CaV3 (Caveolin-3)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on flunarizine + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flunarizine + propranolol.